article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

To help financially weak citizens gain access to affordable healthcare, the Pradhan Mantri Jan Arogya Yojana (PMJAY) was launched in 2018, providing about 500 million Indians with a ₹5 lakh family health insurance cover that include coverage for 1,400 medical procedures as well as critical diseases like prostate cancer.

article thumbnail

Anas Batikhi, Founder & CEO at Santechture Shares on RCM-Tech, A Necessity in The Healthcare Industry

PharmaShots

Anas Batikhi: The healthcare sector, an ongoing evolving industry on its own, is simply a flowing stream of processes, revenues & valuable health outcomes. Getting this process wrong is detrimental to any revenue collections resulting from availing services to the patient.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NHC’s comments in response to the 2025 Notice of Benefit and Payment Parameters (NBPP)

Putting Patients First Blog

Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.

article thumbnail

Low Dose Naltrexone and Hashimoto’s

The Thyroid Pharmacist

LDN was one of the first interventions that I had tried on my thyroid journey back in 2009. Luckily, even without insurance coverage, this medication is available in generic form and is very affordable, usually costing between $15 to $40 per month. It’s a process and a journey, but it’s definitely worth it.

article thumbnail

Top Performing Drug – Enbrel (June Edition)

PharmaShots

In 2009, Pfizer acquired Wyeth thus seeking the rights to Enbrel. Under this agreement, Wyeth and Amgen jointly marketed and sold Enbrel to all appropriate segments in the U.S. and Canada for all approved indications other than oncology. The rights to promote Enbrel in the U.S. and Canada for oncology indications were reserved for Amgen.